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INTRODUCTION 
 Nanoparticles offer improved performance of active ingredients, stability, controlled-delivery, increase comfort and reduce the overall drug content and cost. 
 Nanoparticles are helpful in drug delivery in cases where drugs have poor water solubility.  
 Drugs such as Hydrocortisone (HC) pose a problem, because the right amount of unchanged drug needs to reach the targeted cells. 
 AIM: 
 Produce hydrocortisone nanoparticles using laboratory-fabricated microfluidic devices and investigate a variety of device parameters on nanoparticle properties . 
 Study the effect of stabilisers and polymer on the produced nanoparticles. 
CONCLUSION 
 Nozzle diameter affects the size of nanoparticles produced. 
 HPMC (and other stabilisers) has a major effect on the size and stability of nanoparticles produced. 
FUTURE WORK 
 Production and encapsulation of nanoparticles using counter-current devices and other types of nanopar-
ticles and study of the release rates of drugs encapsulated. 
 Synthesis of Liposomes and Niosomes using both Dispersion Cell and 3D-printed Microfluidic devices to 
encapsulate drugs 
References 
1. Ali, H.S.M., York, P. & Blagden, N., 2009. International 
Journal of Pharmaceutics, 375(1-2), pp.107–113.  
2. Vladisavljević, G., Kobayashi, I. & Nakajima, M., 2012. 
Microfluidics and Nanofluidics, 13(1), pp.151–178.  
Figure 4 — Overlay of DSC thermal profiles of processed and unprocessed HC 
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CHARACTERISATION 
DSC thermal profile of processed and unprocessed HC were analysed, to show the changes in the crystallinity 
of the drug. A sharp peak observed in Figure 7 corresponds to the melting point of the pure unprocessed 
sample. This peak shifted for the processed drug, which indicates the encapsulation of the drug in the poly-
mer and stabilisers. This was corroborated by the XRPD analysis carried out on the processed and unpro-
cessed samples (Figure 8A and 8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Particle Size (nm) 
Aqueous Phase Flow Rate, Qaq: Dispersed Phase 
Flow rate, Qdisp (ml/min) 
t = 0 t + 1 Week t + 1 Month t + 2 Months 
0.6:0.1 251.05 176.90 86.70 150.05 
0.7:0.1 217.27 288.55 95.20 124.60 
Figure 7 Overlay of the DSC thermal profiles of the unprocessed and processed HC  
A B 
Figure 8 XRPD Profile of the (A) Unprocessed and (B) processed HC 
Figure 9 TEM image of HC nanoparticles produced 
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EXPERIMENTAL SET UP 
Experiments were carried out in fabricated glass capillary co-flow microfluidic devices, to synthesise hydrocor-
tisone nanosuspensions. Figures 1 and 2 are the schematic diagrams of the co-flow microfluidic device and 
the experimental set-up of the synthesis of the hydrocortisone nanoparticles respectively while Figure 3 is the 
flow diagram of the steps taken in producing the nanoparticles. 
 
Figure 1 Schematic representation of Co-flow microfluidic device fabricated for 
experiments (A) Side View (B) Bird’s eye view 
A 
B 
High Speed Camera
 
Computer
Aqueous Phase
Microfluidic 
Device
Dispersed 
Phase
Nanosuspensions 
Syringe Pump
Stabilizers
Inverted Microscope 
Figure 2 Schematic diagram of experimental set up for synthesis of nanoparticles  
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Figure 3 Flow chart of experiment 
EXPERIMENTAL RESULTS 
It was observed that increase in flow rate ratio of the aqueous phase to dispersed phase led to decrease in the size 
of nanoparticles produced as shown in Figure 10.  This was expected, as the precipitation formation, which is the 
main force of supersaturation of the solution, being induced by the shorter mixing time of the drug solution and an-
tisolvent, as flow rates are increased thereby reducing the nucleation time. This can also be explained by the in-
creasing Reynolds Number as a result of higher flow rates improving the mixing within the system.  
  
 
 
0
50
100
150
200
250
300
350
400
450
1 2 3 4 5
A
ve
ra
ge
 d
ia
m
et
er
Qaq/Qdisp
0
100
200
300
400
500
600
700
1 2 3 4 5
A
ve
ra
ge
 d
ia
m
et
er
Qaq/Qdisp
Figure 10 Average particle size against flow rate ratio for device nozzle diameter (A) 50µm (B) 
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Hydroxypropyl methylcellulose (HPMC) 
was found to affect the size of nanoparti-
cles produced (Figure  12). HPMC contrib-
uted to the size of nanoparticles formed, 
as it stabilised the HC nanoparticles, in-
creasing stability over a period of time by 
inhibiting the growth of the HC nanopar-
ticles.  
A narrow distribution of the nanoparticles were 
obtained (Figure 11), as evidenced by the value of 
the Polydispersity index obtained during the 
course of the experiments, with values of 0.251 ± 
0.05, indicating a good profile. The sizes of the 
nanoparticles obtained ranged from 158 ± 15nm 
to 332 ± 62nm. 
0
5
10
15
20
25
100 200 300 400 500
D
if
fe
re
n
ti
al
 I
n
te
n
si
ty
 (
%
)
Diameter (nm)
Intensity Distribution
Figure 11 Size distribution of HC nanoparticles 
Figure 12 Effect of HPMC on nanoparticles 
The table shows the stability study over 
a period of 2 months. Gradual reduction 
in the size of measured nanoparticles 
shows the effect of the stabilisers and 
polymer wearing off over a period of 
time. 
NANOPARTICLES FORMATION 
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Figure 4 Production of nanosuspension in the microfluidic device as captured by 
the attached high-speed camera 
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Solubility of Hydrocortisone in Ethanol/Water Mixture
Figure 5  Solubility  of HC in Ethanol/Water mixture 
Drug nanoprecipitation occurred at the exit of inner capillary of the co-
flow microfluidic devices as shown in Figure 4. This contained the organic 
phase - 10mL solution of the drug in 60/40 v/v ethanol in water, and the 
aqueous phase (deionised water) which is contained in the outer capillary 
where the mixture occurs. The formed nanosuspensions were collected in 
stirred vials, containing mixtures of polymer, hydroxypropyl methyl cellu-
lose (HPMC) and stabilisers (Poly Vinyl Pyrrolidone, PVP, and Sodium Do-
decyl Sulfate, SDS). 
Figure 6 Fabricated Co-flow microfluidic device with 
medical tubing attached for delivery and collection  
